A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
मुख्य लेखक: | Karim, Azrin |
---|---|
अन्य लेखक: | Islam, Farzana |
स्वरूप: | Project report |
भाषा: | English |
प्रकाशित: |
Brac University
2024
|
विषय: | |
ऑनलाइन पहुंच: | http://hdl.handle.net/10361/24372 |
समान संसाधन
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
द्वारा: Islam, Saidul
प्रकाशित: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
द्वारा: Ahmed, Nafisa
प्रकाशित: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
द्वारा: Meem, Manila
प्रकाशित: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
द्वारा: Hossain, Sadman Sanjid
प्रकाशित: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
द्वारा: Jahan, Nusrat
प्रकाशित: (2024)